Search

Displaying results 5861 - 5870 of 10000 in total
  1. Drug

    Defoslimod

    go.drugbank.com/drugs/DB20763
    Investigational

    Defoslimod is under investigation in clinical trial NCT01800812 (Effects of OM-174 in Adult Patients With Solid Tumors). Defoslimod has a monoisotopic molecular weight of 1148.65 Da. … The usage of the INN stem '-imod' in the name indicates that Defoslimod is a immunomodulator, both stimulant/suppressive and stimulant.

  2. Drug

    Mevociclib

    go.drugbank.com/drugs/DB21454
    Investigational

    Mevociclib is under investigation in clinical trial NCT03134638 (A Study of SY-1365 in Adult Patients With Advanced Solid Tumors). Mevociclib has a monoisotopic molecular weight of 586.26 Da. … The usage of the INN stem '-ciclib' in the name indicates that Mevociclib is a cyclin dependant kinase inhibitor.

  3. Drug

    Risvodetinib

    go.drugbank.com/drugs/DB21602
    Investigational

    Risvodetinib has a monoisotopic molecular weight of 574.28 Da. … Risvodetinib is under investigation in clinical trial NCT05424276 (A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease).

  4. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

  5. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    [A262051] Prior to 2013, chikungunya virus cases and outbreaks had been identified in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. … Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.[A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus.

  6. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.

  7. Drug

    Aldesleukin

    go.drugbank.com/drugs/DB00041
    ApprovedInvestigational

    This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon … Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.

    Products: PROLEUKIN 18X106 IU/ML STERİL IV LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADET
  8. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain. … Tilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal.

    Synonyms: beta-D-GalactosidaseProducts: LACDIGEST 2250 U CIGNEME TABLETI, 100 TABLET, LACDIGEST 2250 U CIGNEME TABLETI, 50 TABLET
  9. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    Inlexisertib has a monoisotopic molecular weight of 535.29 Da. … Inlexisertib is under investigation in clinical trial NCT05957367 (A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies).

  10. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. … Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.